Medidata Introduces New Support Program for Diverse Clinical Trials
Platform implements patient insights and data to help create diversity action plans.
Medidata announced the launch of its Medidata diversity program, aimed to improve diversity, equity, and inclusion in clinical trials. According to the company, this program supports biopharmaceutical and medical device companies and contract research organizations (CROs) by addressing common systemic and clinical barriers that can hinder a diverse range of individuals from participating in clinical trials.
“Facilitating more diverse participation in clinical trials is a critical and complex challenge, not only for the life sciences industry but for the patients and caregivers participating in the trials,” said Anthony Costello, CEO, Patient Cloud, Medidata. “The Medidata Diversity Program, the most comprehensive solution to date, will help sponsors and CROs move from awareness about a diversity challenge to planning and solving for it as a standard and sustainable part of their clinical development programs.”
Reference: Medidata Launches Industry’s Most Comprehensive Program to Support Clinical Trials Diversity Initiatives. Medidata. September 19, 2023. Accessed September 25, 2023. https://www.medidata.com/en/about-us/news-and-press/medidata-launches-industrys-most-comprehensive-program-to-support-clinical-trials-diversity-initiatives/#:~:text=New%20York%20%E2%80%93%20September%2019%2C%202023,and%20inclusion%20in%20clinical%20trials.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
